Abrdn Life Sciences Investors
HQLFinancial ServicesNASDAQAsset Management
Scan Results
Daily timeframeAbrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The company carries a $539.1M market cap, placing it firmly in the small-cap category. The fund invests in public equity markets across the globe.
Market Cap
$539.1M
Beta
0.73
P/E (TTM)
2.67
P/E (Fwd)
—
EPS (TTM)
$6.65
EPS (Fwd)
—
ROE
41.4%
ROA
-0.6%
Cash
$851,602
Total Debt
$0
Free CF
-$4.4M
52W Change
2.2%
Annual Financials
Cash vs Debt
Where HQL stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, HQL finished 7.29% below its 150-day moving average ($18.10) and 3.78% below its 200-day moving average ($17.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HQL overbought or oversold?
At the October 19, 2026 close, HQL's RSI(14) was 24.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Abrdn Life Sciences Investors reports $852K in cash and $0 in total debt. Free cash flow is running at -$4.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 41.4%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from -$103.3M (2022) to $86.4M (2025), reflecting a 184% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Abrdn Life Sciences Investors and its sector.